Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese Drug Official Sentenced to Four Years in Prison for Taking Bribes (China)

This article was originally published in PharmAsia News

Executive Summary

Zheng Shangjin, previously chief of Zhejiang Provincial Food and Drug Bureau, has been convicted of taking bribes and sentenced to four years in prison by the Yantian District Court in Shenzhen City, south China's Guangdong Province. Shangjin once arranged a meeting between Tang Xudong, president of Kangliyuan Group, his brother Tang Xiaodong, and Zheng Xiaoyu, former director of China's State Food and Drug Administration (SFDA), when the former SFDA chief was in Zhejiang to attend a local fair. He also used his influence to obtain other benefits for the company, according to the court, which also said that as a government official, Shangjin abused his power and accepted bribes totaling 680,000 yuan from the Tang brothers on two separate occasions. (Click here for more - May Require Free Registration

You may also be interested in...

ESMO: Evidence Piles Up For AZ’s Tagrisso With ADAURA CNS Data

A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.

Small Firms Get Year Reprieve From Compliance With US FDA’s Supplement Facts Label Changes

FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.

Bristol/Exelixis Detail Survival Benefit For Opdivo/Cabometyx In Renal Cancer

Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts